However, the cryoablation-induced immune resistance with upregulation of PD-L1 on tumor cells could be overcome by combining cryoablation with a PD-1 inhibitor, such as nivolumab or pembrolizumab, which result in an effective antitumor T-cell response and in more effective disease control [96]. Here, PDCD1 is linked to neoplasm.